Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia

Value in Health(2020)10.1016/j.jval.2020.05.019Source: DataRank Database

Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia is a research paper published in Value in Health (2020). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: bronzeTopics (14)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Ashley L. Cole ORCID,Ashley A. Leech ORCID,William A. Wood ORCID,Stacie B. Dusetzina ORCID,Joehl Nguyen ORCID

Live enrichment

PubMed:19767382

University of North Carolina

Grant: T32LM012420-03

University of North Carolina

Grant: T32-HS000032

National Institutes of Health

Grant: 5T32LM012420-05

Big Data to Knowledge Training Program

National Institutes of Health

Grant: 3T32HS000032-09S1

UNC-CH TRAINING PROGRAM IN HEALTH SERVICES RESEARCH

bronzeLicense: Elsevier TDM

publisherhttp://www.valueinhealthjournal.com/article/S1098301520321732/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1098301520321732?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1098301520321732?httpAccept=text/plain

https://doi.org/10.1016/j.jval.2020.05.019

https://pubmed.ncbi.nlm.nih.gov/33032772

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

Cost-Benefit AnalysisDasatinibAntineoplastic AgentsHealth Care CostsProtein-Tyrosine KinasesDrug CostsDecision Support TechniquesPyrimidinesLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImatinib MesylateHumansQuality-Adjusted Life Years

Sustainable Development Goals

SDG 3: 3. Good health